Loading clinical trials...
Loading clinical trials...
This randomized controlled trial aims to evaluate the impact of Ultra-Fast-Track (UFT) anesthesia on postoperative recovery in patients undergoing elective coronary artery bypass grafting (CABG). UFT anesthesia targets extubation in the operating room or within the first hour after surgery, whereas standard care involves transfer to the intensive care unit (ICU) with subsequent extubation according to routine protocols. A total of 100 patients will be randomized in a 1:1 ratio. The primary outcome is the maximum Vaso-Inotropic Score (VIS) within the first 24 postoperative hours. Secondary outcomes include postoperative pain scores (VAS), Quality of Recovery-15 (QoR-15) scores, opioid and analgesic requirements, ICU and hospital length of stay, time to mobilization, and postoperative complications. This study seeks to determine whether UFT anesthesia can safely reduce inotropic support requirements and enhance early recovery following CABG.
Coronary artery bypass grafting (CABG) is the most frequently performed cardiac surgical procedure and remains the gold standard for the treatment of advanced coronary artery disease. While CABG restores myocardial perfusion and relieves ischemic symptoms, the postoperative period is often associated with prolonged mechanical ventilation, increased risk of complications, higher costs, and delayed recovery. Ultra-Fast-Track (UFT) anesthesia is a perioperative strategy that aims to achieve extubation either in the operating room or within the first postoperative hour. Previous studies have demonstrated that fast-track and UFT protocols may shorten intensive care unit (ICU) length of stay, reduce postoperative complications, and improve recovery, without compromising patient safety. However, the influence of UFT anesthesia on inotropic support requirements, recovery quality, and analgesic needs in patients undergoing CABG has not been fully clarified. In this prospective, randomized, controlled clinical trial, 100 patients scheduled for elective CABG will be randomly assigned to one of two groups: UFT group: patients will undergo standard general anesthesia for cardiac surgery and will be extubated in the operating room or within one hour postoperatively before ICU transfer. Standard care group: patients will undergo the same anesthesia protocol but will remain intubated upon ICU admission, with extubation performed according to routine ICU protocols. The primary endpoint is the maximum Vaso-Inotropic Score (VIS) recorded during the first 24 hours after surgery. Secondary endpoints include postoperative pain scores (VAS), opioid and analgesic requirements, Quality of Recovery-15 (QoR-15) scores at 24 and 72 hours, ICU and hospital length of stay, time to mobilization, and the incidence of postoperative complications such as reintubation, pneumonia, atrial fibrillation, and acute kidney injury. This study is designed to provide high-quality evidence on whether UFT anesthesia can safely decrease inotropic support requirements, enhance postoperative recovery, and reduce ICU stay in patients undergoing CABG.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Adıyaman University Training and Research Hospital
Adıyaman, Adıyaman Province, Turkey (Türkiye)
Start Date
October 1, 2025
Primary Completion Date
December 15, 2025
Completion Date
December 31, 2025
Last Updated
February 10, 2026
100
ACTUAL participants
Ultra-Fast-Track Anesthesia
PROCEDURE
Standart care anesthesia
PROCEDURE
Lead Sponsor
Adiyaman University Research Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT01311323